Cantai Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $3.55M

  • Investors
  • 3

Cantai Therapeutics General Information

Description

Operator of a therapeutics company intended to advance next-generation bispecific antibodies for autoimmune diseases. The company focuses on treating autoimmune and inflammatory disorders by developing cytokine-targeting, enabling patients suffering from immune-mediated and autoimmune diseases to receive effective treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (603)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Therapeutic Devices
Vertical(s)
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (603)

Cantai Therapeutics Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cantai Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 21-Jan-2026 $3.55M Completed Startup
1. Seed Round 20-Nov-2023 Completed Startup
To view Cantai Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cantai Therapeutics Patents

Cantai Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026151915-A1 Il-23 binding antibodies and methods of use Pending 09-Jan-2025
WO-2026064545-A1 Engineered tl1a targeting regions and methods of use Pending 19-Sep-2024
EP-4812501-A1 Engineered bispecific molecules and methods of use Pending 22-Nov-2023
US-20260265389-A1 Engineered bispecific molecules and methods of use Pending 22-Nov-2023
WO-2025111585-A1 Engineered bispecific molecules and methods of use Inactive 22-Nov-2023 C07K16/2875
To view Cantai Therapeutics’s complete patent history, request access »

Cantai Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cantai Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agent Capital Venture Capital Minority
Alloy Therapeutics VC-Backed Company Minority
Tellus BioVentures Venture Capital Minority
To view Cantai Therapeutics’s complete investors history, request access »

Cantai Therapeutics FAQs

  • When was Cantai Therapeutics founded?

    Cantai Therapeutics was founded in 2023.

  • Where is Cantai Therapeutics headquartered?

    Cantai Therapeutics is headquartered in Philadelphia, PA.

  • What is the size of Cantai Therapeutics?

    Cantai Therapeutics has 5 total employees.

  • What industry is Cantai Therapeutics in?

    Cantai Therapeutics’s primary industry is Drug Discovery.

  • Is Cantai Therapeutics a private or public company?

    Cantai Therapeutics is a Private company.

  • What is Cantai Therapeutics’s current revenue?

    The current revenue for Cantai Therapeutics is .

  • How much funding has Cantai Therapeutics raised over time?

    Cantai Therapeutics has raised $6.55M.

  • Who are Cantai Therapeutics’s investors?

    Agent Capital, Alloy Therapeutics, and Tellus BioVentures have invested in Cantai Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process